Author

Pauline Veyrard

SERUM CALPROTECTIN IS NOT EFFECTIVE TO PREDICT IBD RELAPSE AND HAS WEAK DIAGNOSIS ACCURACY
SERUM CALPROTECTIN IS NOT EFFECTIVE TO PREDICT IBD RELAPSE AND HAS WEAK DIAGNOSIS ACCURACY

Pauline Veyrard  et al.

ANTI-USTEKINUMAB ANTIBODIES USING A DRUG TOLERANT ASSAY IS THE ONLY PREDICTIVE FACTOR OF CLINICAL REMISSION IN INFLAMMATORY BOWEL DISEASE PATIENT UNDER USTEKINUMAB
ANTI-USTEKINUMAB ANTIBODIES USING A DRUG TOLERANT ASSAY IS THE ONLY PREDICTIVE FACTOR OF CLINICAL REMISSION IN INFLAMMATORY BOWEL DISEASE PATIENT UNDER USTEKINUMAB

Pauline Veyrard  et al.

IN FAILURE OF NON-OPTIMIZED ADALIMUMAB (ADA) WITH THERAPEUTIC SERUM LEVELS, A CHANGE IN BIOTHERAPY CLASS IS GREATER THAN AN INTENSIFICATION OF ADA DOSE IN PATIENTS WITH CROHN´S DISEASE AND HEMORRHAGIC RECTOCOLITIS
IN FAILURE OF NON-OPTIMIZED ADALIMUMAB (ADA) WITH THERAPEUTIC SERUM LEVELS, A CHANGE IN BIOTHERAPY CLASS IS GREATER THAN AN INTENSIFICATION OF ADA DOSE IN PATIENTS WITH CROHN´S DISEASE AND HEMORRHAGIC RECTOCOLITIS

Pauline Veyrard  et al.

EARLY DETECTION OF ANTI-DRUG-ANTIBODIES USING DRUG-TOLERANT ASSAY WITHIN THE INDUCTION PHASE AT WEEK 2 PREDICTS THE LOSS OF CLINICAL RESPONSE TO ANTI-TNF IN INFLAMMATORY BOWEL DISEASE PATIENTS
EARLY DETECTION OF ANTI-DRUG-ANTIBODIES USING DRUG-TOLERANT ASSAY WITHIN THE INDUCTION PHASE AT WEEK 2 PREDICTS THE LOSS OF CLINICAL RESPONSE TO ANTI-TNF IN INFLAMMATORY BOWEL DISEASE PATIENTS

Pauline Veyrard  et al.

Item 1 - 4 / 4
1